Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indusatumab vedotin
- Development stage
- Phase 2
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Indusatumab vedotin is an antibody-drug conjugate (ADC) developed for the treatment of pancreatic cancer and other gastrointestinal cancers. It consists of a fully human monoclonal antibody (indusatumab) targeting guanylate cyclase 2C (GUCY2C), a receptor overexpressed in certain gastrointestinal tumors, conjugated to the cytotoxic agent monomethyl auristatin E (MMAE). Upon binding to GUCY2C-expressing tumor cells, the ADC is internalized and MMAE is released intracellularly, where it inhibits tubulin polymerization, causing cell cycle arrest at G2/M phase and inducing apoptosis. The drug was in clinical development but its trials were terminated due to insufficient efficacy[1][3][4][5][7].
- Other names
- indusatumab vedotin
02
Targets
GUCY2C (Guanylate cyclase C receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on indusatumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indusatumab vedotin.